Cargando…

NANOG as an adverse predictive marker in advanced non–small cell lung cancer treated with platinum-based chemotherapy

PURPOSE: NANOG is a master transcription factor that regulates stem cell pluripotency and cellular reprograming. Increased NANOG expression has been associated with poor survival in several human malignancies. However, the clinical significance of NANOG overexpression in lung cancer has been scarcel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Boksoon, Park, Myung Jae, Choi, Sue In, In, Kwang Ho, Kim, Chul Hwan, Lee, Seung Hyeun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614794/ https://www.ncbi.nlm.nih.gov/pubmed/29033581 http://dx.doi.org/10.2147/OTT.S144895

Ejemplares similares

Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Lee, Seung Hyeun, et al.
Publicado: (2017)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
por: Paik, Seung Sook, et al.
Publicado: (2018)

High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
por: Yoon, Byung Woo, et al.
Publicado: (2020)

Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study
por: Chang, Boksoon, et al.
Publicado: (2021)

Reactive Oxygen Species Modulator 1 As An Adverse Prognostic Marker In Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy: A Retrospective Pilot Study
por: Kong, Moonkyoo, et al.
Publicado: (2019)

Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum‐based doublet chemotherapy and immunotherapy (SPACE study)
por: Lee, Seung Hyeun, et al.
Publicado: (2021)

The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Song, Ik-Chan, et al.
Publicado: (2015)

Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion
por: Lee, Seung Hyeun, et al.
Publicado: (2017)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

NANOG expression in parthenogenetic porcine blastocysts is required for intact lineage specification and pluripotency
por: Lee, Mingyun, et al.
Publicado: (2023)

Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy
por: Sharma, Jyoti Bhagatram, et al.
Publicado: (2021)

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy
por: Palomba, Grazia, et al.
Publicado: (2014)

MicroRNA-200c as a prognostic and sensitivity marker for platinum chemotherapy in advanced gastric cancer
por: Li, Min, et al.
Publicado: (2017)

Transcriptional properties of human NANOG1 and NANOG2 in acute leukemic cells
por: Eberle, Irina, et al.
Publicado: (2010)

Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
por: Omersa, Daniel, et al.
Publicado: (2016)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy
por: Peng, Yu, et al.
Publicado: (2015)

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Wang, Xiyong, et al.
Publicado: (2017)

Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study
por: Joshi, Amit, et al.
Publicado: (2018)

Mathematical model predicts response to chemotherapy in advanced non-resectable non-small cell lung cancer patients treated with platinum-based doublet
por: Kozłowska, Emilia, et al.
Publicado: (2020)

Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy
por: de Jong, Corine, et al.
Publicado: (2020)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma
por: Zhu, Fubin, et al.
Publicado: (2023)

Significance of stem cell marker Nanog gene in the diagnosis and prognosis of lung cancer
por: Liu, Zeng, et al.
Publicado: (2016)

Differential sequences of exosomal NANOG DNA as a potential diagnostic cancer marker
por: Vaidya, Manjusha, et al.
Publicado: (2018)

Immunoexpression of stem cell markers SOX-2, NANOG AND OCT4 in ameloblastoma
por: Martins Balbinot, Karolyny, et al.
Publicado: (2023)

Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis
por: Chun, Sang Hoon, et al.
Publicado: (2011)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

Clopidogrel-Induced Interstitial Lung Disease: A Case Report
por: An, Jin, et al.
Publicado: (2021)

On the Origin and Evolutionary History of NANOG
por: Scerbo, Pierluigi, et al.
Publicado: (2014)

Nanog Heterogeneity: Tilting at Windmills?
por: Smith, Austin
Publicado: (2013)

Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
por: Zhang, Shiheng, et al.
Publicado: (2016)

Characterization of the Nanog 5′-flanking Region in Bovine
por: Choi, Don-Ho, et al.
Publicado: (2016)

Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer
por: Furqan, Muhammad, et al.
Publicado: (2022)

Esrrb Is a Direct Nanog Target Gene that Can Substitute for Nanog Function in Pluripotent Cells
por: Festuccia, Nicola, et al.
Publicado: (2012)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
por: Hisakane, Kakeru, et al.
Publicado: (2023)

A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiation therapy (PLATINUM trial)
por: Choi, Juwhan, et al.
Publicado: (2022)

Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy
por: Lee, Hee Yeon, et al.
Publicado: (2019)

Prognostic role of apoptosis-related gene functional variants in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
por: Tao, Kai-Yi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_56k26c0ajqjdbhq9cfdr6cnitn